Shares of respiratory devices maker ResMed (NYSE:RMD) dropped more than 6% today after the company reported its Q2 earnings, missing Wall Street’s expectations.
ResMed Inc.
BMC, Apex Medical vow to renew patent battle against ResMed
ResMed buys Czech distributor Unimedis
ResMed (NYSE:RMD) said it bought out Czech medtech distributor Unimedis for an undisclosed amount.
Prague-based Unimedis specializes in sleep-disordered breathing and respiratory care devices in the Czech Republic and Slovakia. Unimedis co-founder Ondrej Kalas will stay on as the country manager for ResMed, according to a press release.
ResMed’s Mick Farrell: “Our primary competitor is ignorance”
The story behind ResMed‘s (NYSE:RMD) meteoric rise from Baxter spinout to $1.5 billion medical device Goliath is no snore.
Or maybe it is. After all, stopping snoring has paid off pretty nicely for the San Diego-based sleep apnea device company, which has a more than 40% share in the growing market for products to diagnose, treat and manage respiratory disorders.